Announcement
Incanthera PLC : Successful Results of Sensitisation Study
RNS Number : 2210A
Incanthera PLC
28 September 2020
28 September 2020
Incanthera plc
("Incanthera" or the "Company")
Sol Skin Cancer Technology
Successful Results of Sensitisation Study
Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce that it has received positive data from a skin sensitisation study of its skin cancer technology Sol.
Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the formation of solar (actinic) keratosis and skin cancer.
The study, conducted by XCellR8 Ltd, has demonstrated that our Sol formulation was found to be "non-irritant" using ex-vivo human skin.
Formerly, studies carried out in collaboration between XCellR8 Ltd and Cutest Ltd (a CRO with particular expertise in clinical trials using topical applications) have demonstrated very good correlation between results using the methodology of this study and those obtained in clinical mildness studies.
Sol's "non-irritancy" was found to be comparable to baby sun protection products tested previously, with Sol scoring better those products which they would define as "very mild".
The Company is delighted with the results, which demonstrate that Sol is "non-irritant". The comfort and safety of human skin's reaction to the topical application of Sol is a further valuable marker of the asset and this technology.
These results add to the data announced on 22 September 2020, showing the exemplary penetration capabilities of Sol into the skin where it could deliver the required bioequivalent level shown to be clinically effective.
Commenting on the announcement, Chairman, Tim McCarthy said:
"This additional positive data on Sol, greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
The directors of the Company take responsibility for this announcement.
For further enquiries:
|
Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
|
|
AQSE Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis |
+44 (0) 20 7213 0880 |
|
|
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge/John Howes/Bob Pountney |
+44 (0) 20 3815 8880 |
Notes to Editors:
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXMZGZLMNRGGZZ
;